{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.1","value":"9.3"},{"groupId":"OG001","spread":"10.7","value":"12.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"1.6","value":"1.1"},{"groupId":"OG001","spread":"6.7","value":"0.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"title":"Cycle 1, Day 1"},{"categories":[{"measurements":[{"comment":"N of 1, pd data not collected from participant","groupId":"OG000","spread":"NA","value":"NA"},{"groupId":"OG001","spread":"7.5","value":"-14.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"title":"Cycle 7, Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"CD19+ peripheral B-cells counts are based on the percentage of total leukocyte population and absolute cell counts.","dispersionType":"Standard Deviation","groups":[{"description":"Cohort 1. 100 mg tabalumab (LY2127399) intravenously (IV) on day 1 of each cycle. Bortezomib (BTZ), 1.3 milligram per square meter (mg/m\\^2), IV on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dexamethasone (Dex), 20 mg/day, on day of and day after BTZ.","id":"OG000","title":"100 mg Tabalumab+BTZ IV+Dex"},{"description":"Cohort 2. 300 mg tabalumab (LY2127399) IV on day 1 of each cycle. BTZ, 1.3 mg/m\\^2, IV on days 1, 4, 8, 11 of Cycle 1-8, then on days 1, 8, 15, 22 from Cycle 9 onward. Oral dex, 20 mg/day, on day of and day after BTZ subcutaneously or intravenously (SC, IV respectively).","id":"OG001","title":"300 mg Tabalumab+BTZ IV+Dex"}],"paramType":"MEAN","populationDescription":"All participants who received at least 1 dose of study drug and had evaluable PD. 300 mg tabalumab IV and SC dose were analyzed together.","reportingStatus":"POSTED","timeFrame":"Baseline, Cycle 1 and Cycle 7: prior to first tabalumab dose.","title":"Pharmacodynamics (PD): Change From Baseline in B-cell Subset Fractions","type":"SECONDARY","unitOfMeasure":"percentage of b-cell change"}